ARGX
Price
$670.94
Change
-$3.96 (-0.59%)
Updated
Aug 6, 04:23 PM (EDT)
Capitalization
41.43B
85 days until earnings call
SLXN
Price
$8.30
Change
-$0.56 (-6.32%)
Updated
Aug 6, 04:51 PM (EDT)
Capitalization
5.13M
Interact to see
Advertisement

ARGX vs SLXN

Header iconARGX vs SLXN Comparison
Open Charts ARGX vs SLXNBanner chart's image
argenx SE
Price$670.94
Change-$3.96 (-0.59%)
Volume$100
Capitalization41.43B
Silexion Therapeutics
Price$8.30
Change-$0.56 (-6.32%)
Volume$200
Capitalization5.13M
ARGX vs SLXN Comparison Chart in %
Loading...
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGX vs. SLXN commentary
Aug 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a StrongBuy and SLXN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 06, 2025
Stock price -- (ARGX: $674.90 vs. SLXN: $8.86)
Brand notoriety: ARGX and SLXN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 112% vs. SLXN: 38%
Market capitalization -- ARGX: $41.43B vs. SLXN: $5.13M
ARGX [@Biotechnology] is valued at $41.43B. SLXN’s [@Biotechnology] market capitalization is $5.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $215.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileSLXN’s FA Score has 1 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • SLXN’s FA Score: 1 green, 4 red.
According to our system of comparison, ARGX is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 6 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).

  • ARGX’s TA Score: 6 bullish, 4 bearish.
  • SLXN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ARGX is a better buy in the short-term than SLXN.

Price Growth

ARGX (@Biotechnology) experienced а +12.71% price change this week, while SLXN (@Biotechnology) price change was -28.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.86%. For the same industry, the average monthly price growth was +14.59%, and the average quarterly price growth was +13.45%.

Reported Earning Dates

ARGX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-0.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGX($41.4B) has a higher market cap than SLXN($5.13M). ARGX YTD gains are higher at: 9.740 vs. SLXN (-70.614). ARGX has higher annual earnings (EBITDA): 690M vs. SLXN (-16.96M). SLXN has less debt than ARGX: SLXN (3.48M) vs ARGX (43.2M). ARGX has higher revenues than SLXN: ARGX (3.05B) vs SLXN (0).
ARGXSLXNARGX / SLXN
Capitalization41.4B5.13M806,389%
EBITDA690M-16.96M-4,069%
Gain YTD9.740-70.614-14%
P/E Ratio34.35N/A-
Revenue3.05B0-
Total Cash3.93BN/A-
Total Debt43.2M3.48M1,241%
FUNDAMENTALS RATINGS
ARGX: Fundamental Ratings
ARGX
OUTLOOK RATING
1..100
23
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
20
SMR RATING
1..100
39
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
86
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARGXSLXN
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
8%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
20%
MACD
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
31%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
42%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
51%
Advances
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 10 days ago
51%
Declines
ODDS (%)
Bearish Trend 20 days ago
63%
Bearish Trend 2 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
44%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SHLD63.121.16
+1.87%
Global X Defense Tech ETF
IWMW38.480.19
+0.51%
iShares Russell 2000 BuyWrite ETF
FAI36.830.08
+0.22%
First Trust Exchange-Traded Fund II
IBTK19.80-0.02
-0.10%
iShares iBonds Dec 2030 Term Trsry ETF
PSCH37.86-0.47
-1.23%
Invesco S&P SmallCap Health Care ETF

ARGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ARGNF. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ARGNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGX
1D Price
Change %
ARGX100%
-2.23%
ARGNF - ARGX
55%
Loosely correlated
N/A
ROIV - ARGX
42%
Loosely correlated
+1.04%
IONS - ARGX
41%
Loosely correlated
-0.92%
GMAB - ARGX
41%
Loosely correlated
+0.55%
AXON - ARGX
40%
Loosely correlated
+16.41%
More

SLXN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLXN has been loosely correlated with IMA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SLXN jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLXN
1D Price
Change %
SLXN100%
-1.99%
IMA - SLXN
59%
Loosely correlated
-0.66%
CELC - SLXN
50%
Loosely correlated
-0.67%
MRSN - SLXN
43%
Loosely correlated
+2.62%
CHRS - SLXN
26%
Poorly correlated
+4.86%
QSI - SLXN
25%
Poorly correlated
N/A
More